Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Serina Therapeutics plans investor outreach at the H.C. Wainwright conference with both a CEO presentation and one-on-one meetings.
Rhea-AI Summary
Serina Therapeutics (SER)/b) will present at the H.C. Wainwright 28th Annual Global Investment Conference, with CEO Steve Ledger delivering the presentation. The conference will be held September 14-16, 2026, in New York, New York, and the company will also participate in one-on-one investor meetings during the event.The presentation will be available for on-demand viewing starting Monday, September 14, 2026, at 7:00 a.m. ET via an online link. Serina is a clinical-stage biotechnology company developing wholly owned drug candidates using its proprietary POZ Platform™ drug optimization technology to treat neurological diseases and other indications. The lead program, SER-252 (POZ-apomorphine), is in development as a long-acting treatment for advanced Parkinson’s disease.
Positive
- None.
Negative
- None.
Details
News Market Reaction – SER
In the Sep 11 session, SER declined 11.20%, reflecting a significant negative market reaction. Argus tracked a trough of -7.9% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. Trading volume was exceptionally heavy at 6.0x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HUNTSVILLE, AL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology enabling drug product candidates to treat neurological diseases and other indications, today announced that Steve Ledger, Chief Executive Officer, will present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference. The Company will also attend one-on-one investor meetings during the conference taking place September 14-16, 2026 in New York, New York.
The presentation will be available for on-demand viewing starting on Monday, September 14, 2026, at 7:00 a.m. ET at this link.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s proprietary POZ Platform™ drug optimization technology is designed to improve the integrated efficacy and safety profile of multiple therapeutic modalities, including small molecules, RNA-based therapeutics and antibody-drug conjugates. The Company’s lead program, SER-252 (POZ-apomorphine), is being developed as a long-acting treatment for advanced Parkinson’s disease. For more information, please visit https://serinatx.com.
For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When and where is Serina Therapeutics presenting at the H.C. Wainwright conference?
Serina Therapeutics will present at the H.C. Wainwright 28th Annual Global Investment Conference, which takes place September 14-16, 2026, in New York, New York. The CEO presentation will be available for on-demand viewing starting Monday, September 14, 2026, at 7:00 a.m. ET.
How can investors access Serina Therapeutics’ presentation?
The company states that the presentation will be available for on-demand viewing via an online link beginning at 7:00 a.m. ET on Monday, September 14, 2026.
What is Serina Therapeutics’ lead drug program?
Serina Therapeutics’ lead program is SER-252 (POZ-apomorphine), which is being developed as a long-acting treatment for advanced Parkinson’s disease.
What does Serina Therapeutics focus on developing?
Serina Therapeutics is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates for neurological diseases and other indications using its proprietary POZ Platform™ drug optimization technology, which is designed to improve the efficacy and safety profile of multiple therapeutic modalities.